Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Does Adding Simehicone To Sodium Phosphate Bowel Preparation Benefit Colonscopy
Bowel preparation has been reported inadequate in 10%-75% of colonoscopic examinations. None of the preparations reached all the requirements of safety, acceptance to patients with negligible discomfort, and rapid cleansing. Polyethyleneglycol is considered as the gold standard for colonoscopic bowel preparation (Grade IA), and aqueous sodium phosphate was an alternative regimen to PEG solution (Grade IA). This consensus also stated that adjunctive therapy, such as bisacodyl, metoclopramide, and simethicone, was shown to improve the quality of bowel preparation. Simethicone works as an adjunct to bowel preparationwith the purpose of diminishing foam formation and improving visualization during colonoscopy. However, the benefit of simethicone in improving colonic bowel preparation, however, was not explored in previous studies.
generic viagra online
IFPMA Director General Michael D. Boyd's Remarks At WHO-UN Meeting With Vaccine CEOs
Mr Secretary General, Madame Director General, Ladies and Gentlemen, we are gathered here today in the shadow of the pandemic influenza threat posed by the Novel A / H1N1 virus.
News of the day
Discovery Of Tiny Protein-Activator Responsible For Brain Cell Damage In Huntington Disease
Johns Hopkins brain scientists have figured out why a faulty protein accumulates in cells everywhere in the bodies of people with Huntington"s disease (HD), but only kills cells in the part of the brain that controls movement, causing negligible damage to tissues elsewhere. The answer, reported this week in Science, lies in one tiny protein called "Rhes" that"s found only in the part of the brain that controls movement. The findings, according to the Hopkins scientists, explain the unique pattern of brain damage in HD and its symptoms, as well as offer a strategy for new therapy.
Public Health

Results And Additional Analyses From Efficacy And Safety Study Of Corthera's Relaxin In Acute Heart Failure To Be Presented At Heart Failure Congress

Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera"s investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France. Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges" Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure. About Corthera Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera"s lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. Corthera Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009